Opendata, web and dolomites

NOVA-MRI SIGNED

Novel Applications in 19F Magnetic Resonance Imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVA-MRI project word cloud

Explore the words cloud of the NOVA-MRI project. It provides you a very rough idea of what is the project "NOVA-MRI" about.

mri    insights    nanoparticles    renal    active    gbcas    repeated    generation    invasive    modality    cell    clinical    absolutely    announcement    basis    imaged    whilst    competing    smart    tolerated    move    perfluorocarbon    regarding    reagents    individual    opened    safe    biomaterial    gbca    gadolinium    animals    mounting    door    risk    cells    until    resonance    patients    background    resolution    impairment    area    body    safety    inside    limit    incorporated    signal    imaging    spurred    fda    historically    labelled    functionalisation    kidneys    2015    structures    19f    deposits    discrimination    accumulate    advised    generally    found    magnetic    accumulated    healthcare    technique    therapeutic    quantitative    signatures    situations    materials    diagnostic    bone    molecular    agents    visualised    professionals    living    deemed    surrounding    tissue    migration    tissues    novelty    brain    multifunctional    ligands    administered    preclinical    payload    biology    expansion    released    trafficking    contrast   

Project "NOVA-MRI" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 4˙051˙634 €
 EC max contribution 4˙051˙634 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 796˙859.00
2    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 606˙345.00
3    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 303˙172.00
4    POLYPURE AS NO (OSLO) participant 292˙342.00
5    PERCUROS BV NL (LEIDEN) participant 265˙619.00
6    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 265˙619.00
7    UNIVERSITA DEGLI STUDI DI CAMERINO IT (CAMERINO) participant 261˙499.00
8    CROZET MEDICAL GMBH DE (DUSSELDORF) participant 252˙788.00
9    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 252˙788.00
10    MEDRES-MEDICAL RESEARCH GMBH DE (KOLN) participant 252˙788.00
11    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ES (SAN SEBASTIAN) participant 250˙904.00
12    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 250˙904.00

Map

 Project objective

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique that is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

 Publications

year authors and title journal last update
List of publications.
2020 Somayeh Rezaei, Soheila Kashanian, Yadollah Bahrami, Luis J. Cruz, Marjan Motiei
Redox-Sensitive and Hyaluronic Acid-Functionalized Nanoparticles for Improving Breast Cancer Treatment by Cytoplasmic 17α-Methyltestosterone Delivery
published pages: 1181, ISSN: 1420-3049, DOI: 10.3390/molecules25051181
Molecules 25/5 2020-04-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVA-MRI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVA-MRI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More  

LongActNow (2019)

Long Acting Medicines for Complex Therapeutics Needed Now

Read More